Sotatercept(TD-HY428026) is a research-grade recombinant antibody targetingEDF. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Functional assay, Research in vivo
Isotype
Fusion - [ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2 - IGHG1 Fc (Fragment constant)
Protein A/G purified from cell culture supernatant.
Accession
P08476
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.
Caption
SDS-PAGE for Research Grade Sotatercept
Note
For research use only. Not suitable for clinical or therapeutic use.